Replies to Post #181954 onBiotech Values

Replies to post #181954 on Biotech Values

Replies to #181954 on Biotech Values

10/16/14 8:56 AM

#182839 RE: DewDiligence #181954

Factoid: BAX minus the planned BXLT spinoff currently derives 25% of sales from emerging markets.

12/10/14 6:10 PM

#184578 RE: DewDiligence #181954

BAX files SEC form for Baxalta (pharma segment) spinoff:

http://www.sec.gov/Archives/edgar/data/1620546/000119312514439061/d829725dex991.htm